Syed Sadatullah Hussaini is the new National President of Jamat-e-Islami Hind
New Delhi: Former National President of Students Islamic Organisation of India (SIO) a student’s wing of Jamat-e-Islami Hind (JIH) and current vice-president of JIH, Syed Sadatullah Hussaini has been elected as the Ameer (National President) of JIH for a four year term from April 2019 to March 2023.
At the age of 46 years, Syed Sadatullah Hussaini is the youngest ever Ameer of the JIH, while some have claimed Moulana Abullais Islahi (first Ameer of JIH) was the youngest to serve the position. There has been no official clarification in this regard as yet. He was the president of SIO for two consecutive terms between 1999 and 2003.
Syed Sadatullah Hussaini was elected by Jamaat’s 157 member Markazi Majlis-e Numanidgan (Council of Representatives) after thorough deliberations on all aspects and replaced Moulana Jalaluddin Umri, who served the top position of JIH from 2007 to 2019.
Born in Nanded, Maharashtra in 1973, Syed Sadatullah Hussaini holds a bachelor degree in Electronics and Telecommunication Engineering and has authored 12 books and more than 200 articles in English and Urdu languages.
Syed Sadatullah Hussaini elected new Ameer of Jamaat-e-Islami Hind#WelcomeAmeerJIHhttps://t.co/KhJSTv3IpG pic.twitter.com/4pxXEsHnFM
— Jamaat-e-Islami Hind (@JIHMarkaz) April 6, 2019
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Ballari maternal deaths: Karnataka govt. seeks explanation from CDSCO
Bengaluru: The Karnataka Government has sought clarification from the Central drugs standard control organisation following reports linking the serial deaths of pregnant women at Ballari District Hospital to unsafe IV Ringer's Lactate solution. Health Department Principal Secretary Harsha Gupta has written a letter to the Drugs Controller General of India, Rajeev Singh Raghuvanshi.
Recent Investigations revealed bacterial and fungal contaminants in the IV solution given to the women. Out of 192 batches supplied by a West Bengal-based pharmaceutical company, 22 were found substandard by the state drug control department, leading to the suspension of the medicine's use.
However, these batches had passed quality tests at the Central Drug Lab, creating a regulatory conflict.
The Health Department emphasized adherence to tender rules, stating that the Central Drug Lab's approval is legally binding. Samples from the problematic batches have been sent for re-testing at the central lab in West Bengal, with results expected on December 9.
As a precautionary measure, the state has blacklisted the implicated batches and issued directives to halt their use in all hospitals.
